4DMedical Limited
4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in the medical research technology and development of a non-invasive respiratory imaging solution using four-dimensional imaging. It offers CT:VQ, non contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function im… Read more
4DMedical Limited (FDMDF) - Net Assets
Latest net assets as of June 2025: $64.24 Million USD
Based on the latest financial reports, 4DMedical Limited (FDMDF) has net assets worth $64.24 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($94.81 Million) and total liabilities ($30.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $64.24 Million |
| % of Total Assets | 67.75% |
| Annual Growth Rate | 61.47% |
| 5-Year Change | -22.94% |
| 10-Year Change | 6832.03% |
| Growth Volatility | 148.82 |
4DMedical Limited - Net Assets Trend (2015–2025)
This chart illustrates how 4DMedical Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 4DMedical Limited (2015–2025)
The table below shows the annual net assets of 4DMedical Limited from 2015 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $64.24 Million | -9.43% |
| 2024-06-30 | $70.93 Million | -0.75% |
| 2023-06-30 | $71.46 Million | +20.08% |
| 2022-06-30 | $59.51 Million | -28.61% |
| 2021-06-30 | $83.36 Million | +805.82% |
| 2020-06-30 | $-11.81 Million | -359.23% |
| 2019-06-30 | $4.56 Million | +20.58% |
| 2018-06-30 | $3.78 Million | +16.27% |
| 2017-06-30 | $3.25 Million | +250.68% |
| 2016-06-30 | $926.64K | +73.88% |
| 2015-06-30 | $532.93K | -- |
Equity Component Analysis
This analysis shows how different components contribute to 4DMedical Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18115093000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $239.97 Million | 373.58% |
| Other Comprehensive Income | $6.37 Million | 9.92% |
| Total Equity | $64.24 Million | 100.00% |
4DMedical Limited Competitors by Market Cap
The table below lists competitors of 4DMedical Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VEF AB (Publ)
PINK:VEFFF
|
$137.92 Million |
|
Yatas Yatak ve Yorgan Sanayi Ticaret AS
IS:YATAS
|
$137.93 Million |
|
Lucky Strike Entertainment Corporation
NYSE:LUCK
|
$137.97 Million |
|
Baozun Inc
NASDAQ:BZUN
|
$138.03 Million |
|
Kaveri Seed Company Limited
NSE:KSCL
|
$137.91 Million |
|
Shanghai Karon Eco-Valve Manufacturing Co. Ltd.
SHE:301151
|
$137.84 Million |
|
Modiv Inc
NYSE:MDV
|
$137.82 Million |
|
Kelly Partners Group Holdings Limited
OTCQX:KPGHF
|
$137.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 4DMedical Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 70,926,649 to 64,235,164, a change of -6,691,485 (-9.4%).
- Net loss of 30,069,854 reduced equity.
- Share repurchases of 1,360,787 reduced equity.
- New share issuances of 14,703,355 increased equity.
- Other comprehensive income increased equity by 1,838,753.
- Other factors increased equity by 8,197,048.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-30.07 Million | -46.81% |
| Share Repurchases | $1.36 Million | -2.12% |
| Share Issuances | $14.70 Million | +22.89% |
| Other Comprehensive Income | $1.84 Million | +2.86% |
| Other Changes | $8.20 Million | +12.76% |
| Total Change | $- | -9.43% |
Book Value vs Market Value Analysis
This analysis compares 4DMedical Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.25x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.01x to 2.25x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-06-30 | $35.79 | $0.34 | x |
| 2016-06-30 | $37.70 | $0.34 | x |
| 2017-06-30 | $0.02 | $0.34 | x |
| 2018-06-30 | $0.02 | $0.34 | x |
| 2019-06-30 | $0.03 | $0.34 | x |
| 2020-06-30 | $-0.04 | $0.34 | x |
| 2021-06-30 | $0.32 | $0.34 | x |
| 2022-06-30 | $0.20 | $0.34 | x |
| 2023-06-30 | $0.24 | $0.34 | x |
| 2024-06-30 | $0.19 | $0.34 | x |
| 2025-06-30 | $0.15 | $0.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 4DMedical Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -46.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -513.72%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.48x
- Recent ROE (-46.81%) is above the historical average (-62.78%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -26.09% | -54.99% | 0.37x | 1.27x | $-192.32K |
| 2016 | -86.94% | -226.93% | 0.32x | 1.19x | $-887.86K |
| 2017 | -122.29% | -206438.29% | 0.00x | 1.52x | $-4.30 Million |
| 2018 | -104.20% | -498.82% | 0.14x | 1.44x | $-4.31 Million |
| 2019 | -142.48% | -933.96% | 0.08x | 1.98x | $-6.95 Million |
| 2020 | 0.00% | -1782.99% | 0.08x | 0.00x | $-20.79 Million |
| 2021 | -25.70% | -9872.21% | 0.00x | 1.11x | $-29.76 Million |
| 2022 | -41.32% | -2332.63% | 0.01x | 1.25x | $-30.54 Million |
| 2023 | -44.02% | -4378.04% | 0.01x | 1.30x | $-38.61 Million |
| 2024 | -50.73% | -1179.76% | 0.03x | 1.69x | $-43.07 Million |
| 2025 | -46.81% | -513.72% | 0.06x | 1.48x | $-36.49 Million |
Industry Comparison
This section compares 4DMedical Limited's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 4DMedical Limited (FDMDF) | $64.24 Million | -26.09% | 0.48x | $137.91 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |